Loading...
 

Volume 33, Issue 2, June 2022



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(2):224-31
Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study
Authors Information

1Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco

2Laboratory of Biostatistical, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

3Department of Rheumatology, Provincial Hospital of Temara, Morocco

4Department of Rheumatology, Military Hospital Mohammed V, Ibn Sina University Hospital, Rabat, Morocco

5Department of Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco

6Department of Rheumatology, Arrazi University Hospital, Marrakech, Morocco

7Private Medical Office, Rabat, Morocco

8Department of Rheumatology, University Hospital of Agadir, Morocco

9. Department of Rheumatology, Military Hospital Moulay Ismail, Hassan II University Hospital, Meknès - Morocco.

10Department of Rheumatology, Hassan II University Hospital, Fès, Morocco.

11Department of Rheumatology, Mohammed VI University Hospital, Oujda, Morocco

12Department of Rheumatology, Ibn Rochd University Hospital, Casablanca, Morocco

13Department of Rheumatology, Military Hospital Avicenne, Mohammed VI University Hospital, Marrakech, Morocco

Abstract

Objectives: The aim of this study was to determine the therapeutic maintenance level of methotrexate for rheumatoid arthritis patients enrolled in the Moroccan biotherapy registry and to identify predictive factors for discontinuing MTX treatment.

Methods: A cross-sectional study was conducted using the baseline data of the Moroccan biotherapy registry for RBSMR (a multicentric study that aims to evaluate tolerance of biological therapy on patients affected with rheumatic diseases). Demographics and disease features were compared using descriptive statistics. Therapeutic maintenance levels were determined according to a Kaplan-Meier survival curve and a univariate Cox proportional hazards regression model was used to compare the strength of potential factors, followed by a multivariate Cox model to identify significant predictors of MTX discontinuation. Statistically significant results were considered for p values less than 0.05.

Results: 224 patients with rheumatoid arthritis were included in this study. The mean age of patients was 51.83±11.26 years with a majority of females (87.50%). The median duration of disease was 12 [1.66-41.02] years. The therapeutic maintenance level of MTX was 91.1% at 1 year, 87.1% at 2 years, and 68.3% at 5 years. The median of treatment duration was 2, 02 [0, 46-27,76] years. Causes of treatment interruption were side effects (66/88=75%), inefficiency (12/88=13.63%), and other reasons (10/88=11.36%). Predictive factors for stopping MTX were presence of rheumatoid factor (HR 2.24; 95% CI 1.14-5.15; p=0.02) and the access to education (HR 0.37; 95% CI 0.16-0.88; p=0.02).

Conclusion: The therapeutic maintenance level of MTX in our study was satisfactory and comparable to other series, and influenced by many factors such as the occurrence of a side effect. It is necessary to sensitise medical practitioners on symptomatic prevention and management of side effects.


Cite this article as: Oulkadi L, Rostom S, Hmamouchi I, El Binoune I, Amine B, Abouqa R, Achemla L, Allali F, El Bouchti I, ElMaghraoui A, Ghozlani I, Hassikou H, Harzy T, Ichchou L, Mkinsi O, Niamane R, Bahiri R. Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study. Mediterr J Rheumatol 2022;33(2):224-31

Article Submitted: 13 Jun 2021; Revised Form: 17 May 2022; Article Accepted: 30 May 2022; Available Online: 30 Jun 2022

https://doi.org/10.31138/mjr.33.2.224

This work is licensed under a Creative Commons Attribution 4.0 International License.

©Oulkadi L, Rostom S, Hmamouchi I, El Binoune I, Amine B, Abouqa R, Achemla L, Allali F, El Bouchti I, ElMaghraoui A, Ghozlani I, Hassikou H, Harzy T, Ichchou L, Mkinsi O, Niamane R, Bahiri R.